Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen

TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, ...

November 20, 2022, 6:30 pm

Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen

TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, ...

November 20, 2022, 6:30 pm

Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen

TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, ...

November 20, 2022, 6:30 pm

Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen

TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, ...

November 20, 2022, 6:30 pm

Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen

TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, ...

November 20, 2022, 6:30 pm

Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen

TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, ...

November 20, 2022, 6:30 pm

Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen

TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, ...

November 20, 2022, 6:30 pm

Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen

TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, ...

November 20, 2022, 6:30 pm

Tesla safety at centre of south korean trial over fiery, fatal crash

In an upscale Seoul neighbourhood two years ago, a white Tesla Model X smashed into a parking lot wall. The fiery crash killed a prominent lawyer - a ...

November 20, 2022, 6:03 pm

Dr. scott gottlieb on two positive covid cases on royal caribbean cruise ship

Former FDA commissioner Dr. Scott Gottlieb joins ‘Closing Bell' to discuss the two positive Covid cases on a Royal Caribbean ship. He adds that he h...

November 19, 2022, 2:14 am

Why algonquin power & utilities stock plunged below $8 this week

The utility stock's latest warning raises concerns about the safety of its 9.4% dividend yield....

November 18, 2022, 2:34 pm

2 very safe stocks to invest in right now

These companies offer investors many safety features....

November 18, 2022, 7:05 am

Fortive corporation readjusts strategies to achieve growth and margin

Healthcare has become one of Fortive Corporation's leading revenue drivers, mainly because of the recurring revenue stream. It also looks to score big...

November 17, 2022, 5:06 pm

Editas medicine announces clinical data demonstrating proof of concept of edit-101 from phase 1/2 brilliance trial

EDIT-101 demonstrates a favorable safety profile across all dose cohorts Preliminary efficacy signals o...

November 17, 2022, 12:15 pm

Kulr technology announces support for nasa’s artemis program with launch of kulr’s cubesat lithium-ion battery

KULR Battery Product Meets Top safety Requirements Outlined by JSC 20793 Created by NASA From the Inter...

November 16, 2022, 9:15 pm

Mastercard (ma) unveils google wallet for card users in malaysia

Mastercard (MA) launches Google Wallet to extend the app's multiple benefits to Malaysia's customers and also looks to employ its tokenization technol...

November 16, 2022, 5:18 pm

Kulr technology cubesat to support nasa space program, including artemis mission to the moon

KULR Technology Group Inc said its new CubeSat Lithium-ion battery pack format will support the NASA space program and Artemis missions to the moo...

November 16, 2022, 4:54 pm

Us federal reserve speakers on wednesday, 16 november 2022 - williams, barr, waller

1450 GMT Federal Reserve Bank of New York President John Williams speaks before 2022 U.S. Treasury Market Conference

1500 GMT Federal Reserv...

November 16, 2022, 4:44 am

Tesla reports two new fatal crashes involving driver assistance systems

Tesla Inc told U.S. auto safety regulators it has reports of two new crash fatalities in Model 3 cars t...

November 15, 2022, 11:53 pm

Bookingcentral.com adds features to address florida boating safety act sb 606

SANTA ROSA BEACH, Fla., Nov. 15, 2022 (GLOBE NEWSWIRE) — BookingCentral.com, a provider of booking systems for boat rental and watersports businesse...

November 15, 2022, 7:00 pm